GlassScriptPhysician profile
Jill A Hughes
NPI 1013364785
$2,122.93
in general payments reported to CMS, 2019-2025
34 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $134 · 2023: $34.34 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.64 |
| Education | $469.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $364.65 | 2025 | Enhertu, Imfinzi, Calquence |
| Janssen Biotech, INC. | $292.52 | 2025 | Erleada, Tremfya, Balversa |
| Abbvie INC. | $288.21 | 2021-2025 | |
| Astellas Pharma US INC | $159.55 | 2025 | Padcev, Vyloy |
| Polymedics Innovations INC. | $86.61 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $85.50 | 2025 | Keytruda, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $64.45 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $52.38 | 2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $50.28 | 2025 | |
| Celgene Corporation | $47.53 | 2025 | Reblozyl |
| Lilly USA, LLC | $45.61 | 2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $44.72 | 2025 | |
| Beone Medicines USA, INC. | $41.99 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $41.76 | 2025 | |
| Emd Serono, INC. | $37.29 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $33.88 | 2025 | Amtagvi |
| Convatec INC. | $31.79 | 2021 | |
| Genentech USA, INC. | $30.20 | 2025 | Polivy |
| Pharmaessentia USA Corporation | $29.59 | 2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $26.54 | 2025 | Ninlaro |
| Accord Healthcare, INC. | $23.76 | 2025 | |
| Sobi, INC | $23.34 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $22.65 | 2021 | |
| Daiichi Sankyo INC. | $22.25 | 2025 | Datroway |
| Genmab U.S., INC. | $22.10 | 2025 | Epkinly |
| Smith+Nephew, INC. | $22.00 | 2021 | |
| Recordati_rare_diseases_inc. | $20.79 | 2025 | Enjaymo |
| Hydrofera LLC | $20.03 | 2021 | |
| Syndax Pharmaceuticals, INC. | $18.57 | 2025 | |
| Exelixis INC. | $16.29 | 2025 | Cabometyx |
| Novocure INC. | $16.22 | 2025 | Optune Lua (Novottf-200t) |
| Eisai INC. | $14.22 | 2025 | |
| Puma Biotechnology, INC. | $13.59 | 2025 | |
| Kci USA, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.